11 bio-ct what we are what we are not what we are expected to do gabriel merguimanuel vega bio-c.t....
TRANSCRIPT
1 1
BIO-CT
What we areWhat we are not
What we are expected to do
Gabriel Mergui Manuel Vega
Bio-C.T. Workshop Turin Feb 2010
2
Research Industry Market
The Innovation process: where are we?
2Bio-C.T. Workshop Turin Feb 2010
Bio-C.T. Workshop Turin Feb 2010 3
4
Industry
Risk : controlled
Financing: private (and public)
Public Research
Risk: the notion is absent or recent
Financing : public
scientificPoC
Very scarcely, the PoC is mature enough: the industry may in-licence directly…
Scenario 0
Bio-C.T. Workshop Turin Feb 2010
5
Industry or
Venture Capital Take over
Risk : controlled
Financing: private (and public)
Public Research
Risk: the notion is absent or recent
Financing : public
scientificPoC
… but in most cases there is a need for further maturation to obtain ‘industrial’ PoC
industrialPoC
Maturation
Bio-C.T. Workshop Turin Feb 2010
6
Industry or
Venture Capital Take over
Public Research
scientificPoC
Maturation is plenty of uncertainties and risks…
industrialPoC
Business sense ?
Market ? Clients ? Competitors ?
Intellectual property ?
Validation of scientific POC ?..
…In animals ? …In humans ?
Prototype ?
Manufacturing ? Up-scaling ?
Regulatory frame ?
Bio-C.T. Workshop Turin Feb 2010
7
Industry or
Venture Capital Take over
Public Research
scientificPOC
…it is the so-called Death Valley
industrialPOC
« Death Valley »
Maturation
Risk: very high
The maturation process is not ‘spontaneous’
(Each side says: “It’s not our Job”)Bio-C.T. Workshop Turin Feb 2010
8
The objectives of BIO-CT
Phase 1 : To identify appropriate Tools (human, technical and financial) available in the partnering Bio-Regions and likely to be shared in support to the maturation of innovative biotechnology projects
Method: Performing a SWOT analysis for each Bio-Region to identify the human, technical and financial Tools available or lacking in each Bio-Region and their suitability for sharing between Bio-Regions.
8Bio-C.T. Workshop Turin Feb 2010
9
The objectives of BIO-CT
Year 2 : To deliver an implementation roadmap (Joint Action Plan and Business Plan) for the maturation of innovative biotechnology projects at the European level:
- While maximizing the sharing of existing tools available in the Bio-Regions;
- For selected projects within or without a Company;
-Up to the industrial PoC (Industry take over or VC investment).
Bio-C.T. Workshop Turin Feb 2010
10
Scenario 1
…in the presence of a founder entrepreneur
• Relies on the founding endeavor of an entrepreneur..
• Is the technology / product validated enough? / Is company creation too early?
• Why is it so difficult for certain companies to raise VC investment?
The classic model is not perfect…
Bio-C.T. Workshop Turin Feb 2010
11
Scenario 1
Board of Directors
Founder entrepreneur
Company
Private investors
Scenario 2
Surveillance Committee
Project leader
Project (contract)
“Public” financing
Shared Tools
Human
Human
Human + Technical (platforms, facilities,
maturation instruments)
Financial
Tools : Scenario 1 vs Scenario 2
Bio-C.T. Workshop Turin Feb 2010
12
Basic criteria for the selection of appropriate Toolsto be shared in the
Project Maturation Process (Scenarios 1 & 2)
Candidate Tools for sharing between Bio-Regions to be selected according to specific criteria:
- Consistency with Maturation process
- Excellence (Qualified, Labeled, )
- Accessibility (Technical, Legal, Financial, ……)
Bio-C.T. Workshop Turin Feb 2010
1313
Thanks
13Bio-C.T. Workshop Turin Feb 2010